4 - Autonomix Medical, Inc. (0001617867) (Issuer)

4 - Autonomix Medical, Inc. (0001617867) (Issuer)

4 - Autonomix Medical, Inc. (0001617867) (Issuer)

4 - Autonomix Medical, Inc. (0001617867) (Issuer)

4 - Autonomix Medical, Inc. (0001617867) (Issuer)

3 - Autonomix Medical, Inc. (0001617867) (Issuer)

4 - Autonomix Medical, Inc. (0001617867) (Issuer)

POS AM - Autonomix Medical, Inc. (0001617867) (Filer)

10-K - Autonomix Medical, Inc. (0001617867) (Filer)

8-K - Autonomix Medical, Inc. (0001617867) (Filer)

EFFECT - Autonomix Medical, Inc. (0001617867) (Filer)

S-3/A - Autonomix Medical, Inc. (0001617867) (Filer)

S-3 - Autonomix Medical, Inc. (0001617867) (Filer)

8-K - Autonomix Medical, Inc. (0001617867) (Filer)

8-K - Autonomix Medical, Inc. (0001617867) (Filer)

10-Q - Autonomix Medical, Inc. (0001617867) (Filer)

8-K - Autonomix Medical, Inc. (0001617867) (Filer)

Expansion of study into additional indications doubles the potential addressable market beyond pancreatic cancer pain PoC 2 phase builds on early success and positive results demonstrated in PoC 1 in patients with severe pancreatic cancer pain, supporting multi-indication growth strategy THE WOODLANDS, TX, June 30, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ:AMIX) ("Autonomix" or the "Company"), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced the first patient has been enrolled and treated in the follow-on phase to its proof-of-concept human clinical tr

Patent supports the Company's broader mission to advance minimally invasive, nerve-focused treatments across high-need indications Strengthens strategic position in a multi-billion-dollar market opportunity and expands Autonomix's growing global IP portfolio with over 80 issued patents THE WOODLANDS, TX, June 27, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ:AMIX) ("Autonomix" or the "Company"), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 12,279,889 B2 (the ‘889 patent) titled, "Systems and Methods for Neurological Traffic and/or Receptor F

Follow-on study ("PoC 2") builds on initial success in pancreatic cancer pain  Ethics committee authorization supports platform expansion into visceral cancer pain for proprietary ablation technology Expansion supports Autonomix's strategy to build long-term value through multi-indication growth Patient enrollment expected to begin in June 2025 THE WOODLANDS, TX, June 05, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ:AMIX) ("Autonomix" or the "Company"), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced that it has received Ethics Committee authorization

Patent strengthens Autonomix's intellectual property position in the nerve-mapping and denervation space, supporting the Company's broader mission to advance minimally invasive, nerve-focused therapeutics Company continues to expand its growing global patent portfolio with over 80 issued patents and 40 pending patent applications THE WOODLANDS, TX, May 15, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ:AMIX) ("Autonomix" or the "Company"), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 12,257,071 (‘071 patent) titled Controlled sympathectomy an

Live webcast followed by an interactive Q&A session on Thursday, May 22nd at 4:00 PM ET Access the event here THE WOODLANDS, TX, May 14, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ:AMIX) ("Autonomix" or the "Company"), a medical device company focused on advancing precision nerve-targeted treatments, today announced it will participate in the Virtual Investor Closing Bell Series on Thursday, May 22, 2025 at 4:00 PM ET. As part of the event, Brad Hauser, President and Chief Executive Officer of Autonomix, will provide a corporate overview and discuss the Company's first-in-class platform system technology, a catheter-based microchip sensing array that may have the ability t

Discussion in Virtual Investor CEO Connect focuses on Company's planned follow-on market expansion study phase ("PoC 2") of proof-of-concept trial; Access Here Additional indications potentially double the addressable market beyond pancreatic cancer pain Follow-on expansion phase expected to begin in Q2 2025 THE WOODLANDS, TX, May 13, 2025 (GLOBE NEWSWIRE) -- – Autonomix Medical, Inc. (NASDAQ:AMIX) ("Autonomix" or the "Company"), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today reiterated its plans for a follow-on phase to its proof-of-concept human clinical trial ("PoC 2")

Video testimonial demonstrates pain reduction after transvascular nerve ablation, suggesting potential for improving quality of life in late-stage cancer care Patient testimonial now available here THE WOODLANDS, TX, May 05, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ:AMIX) ("Autonomix" or the "Company"), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced the release of a new video testimonial from a patient participating in the initial phase of its first-in-human proof-of-concept trial ("PoC 1") evaluating the safety and effectiveness of delivering transv

Dr. Robert Schwartz, Chief Medical Officer of Autonomix, discusses key learnings from initial trial phase ("POC 1") where clinically meaningful pain reduction was demonstrated Outlines Company's plans to initiate market expansion study ("POC 2") into additional visceral cancers and earlier stage pancreatic cancer, expected to begin Q2 2025 Access the "What This Means" video here THE WOODLANDS, TX, May 01, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ:AMIX) ("Autonomix" or the "Company"), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced that it recently pa

Initial trial phase ("PoC 1") achieved key learnings and met all study objectives Clinically meaningful pain reduction with 100% of responders achieving zero opioid use at 7 days post-procedure and 73% of responders remaining opioid free at 4-6 week follow-up Company has initiated market expansion study ("PoC 2") of additional visceral cancers, and earlier stage pancreatic cancer, to begin in Q2 2025 Additional indications potentially double the addressable market beyond pancreatic cancer pain THE WOODLANDS, TX, April 30, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ:AMIX) ("Autonomix" or the "Company"), a medical device company focused on advancing innovative technologies

THE WOODLANDS, TX, April 17, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ:AMIX) ("Autonomix" or the "Company"), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced that the Compensation Committee of Autonomix's Board of Directors approved the grant of an inducement stock option on April 17, 2025 to purchase 5,000 shares of the Company's common stock, to a new non-executive employee pursuant to the Nasdaq Rule 5635(c)(4) inducement grant exception, as a component of the individual's employment compensation and was granted as an inducement material to their star

Continued efforts to build team and infrastructure required to support clinical and regulatory initiatives in anticipation of the FDA approval process for first-in-class catheter-based sensing technology Company remains on track to submit an Investigational Device Exemption ("IDE"), and if approved, will commence a pivotal clinical trial in 2025 to support a De Novo application for FDA approval THE WOODLANDS, TX , Dec. 19, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ:AMIX) ("Autonomix" or the "Company"), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced th

Former President and Chief Executive Officer, Lori Bisson, appointed as Executive Vice Chairman THE WOODLANDS, TX, June 17, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ:AMIX) ("Autonomix" or the "Company"), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced changes to its executive leadership team to support its next pivotal phase of development. Effective immediately, Brad Hauser has been appointed as President and Chief Executive Officer. Additionally, Lori Bisson, former President and Chief Executive Officer, has been appointed Executive Vice Chairman

Proven executive with 28 years of success building winning B2C & B2B businesses, brands, and teams for premier consumer, healthcare, and medical technology brands THE WOODLANDS, TX, March 19, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ:AMIX) ("Autonomix" or the "Company"), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced the appointment of Jennifer Cook as its Chief Business Officer. Mrs. Cook is an innovative, cross-functional leader with significant expertise working with early developmental stage companies and building them into fully integrated c

SC 13G - Autonomix Medical, Inc. (0001617867) (Subject)

SC 13G - Autonomix Medical, Inc. (0001617867) (Subject)

SC 13G - Autonomix Medical, Inc. (0001617867) (Subject)

SC 13D - Autonomix Medical, Inc. (0001617867) (Subject)